Bicycle Therapeutics (BCYC)
NASDAQ:BCYC
Want to see BCYC full AI Analyst Report?
Total Valuation
Bicycle Therapeutics has a market cap or net worth of $303.92M. The enterprise value is -$244.31M.
Market Cap$303.92M
Enterprise Value-$244.31M
Share Statistics
Bicycle Therapeutics has 50,373,280 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding50,373,280
Owned by Insiders23.08%
Owned by Institutions55.30%
Financial Efficiency
Bicycle Therapeutics’s return on equity (ROE) is -0.36 and return on invested capital (ROIC) is -37.34%.
Return on Equity (ROE)-0.36
Return on Assets (ROA)-0.31
Return on Invested Capital (ROIC)-37.34%
Return on Capital Employed (ROCE)-0.37
Revenue Per Employee237.99K
Profits Per Employee-717.90K
Employee Count305
Asset Turnover0.10
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bicycle Therapeutics is ―. Bicycle Therapeutics’s PEG ratio is -0.26.
PE Ratio―
PS Ratio6.76
PB Ratio0.80
Price to Fair Value0.80
Price to FCF-1.94
Price to Operating Cash Flow-1.32
PEG Ratio-0.26
Income Statement
In the last 12 months, Bicycle Therapeutics had revenue of 72.59M and earned -218.96M in profits. Earnings per share was -3.16.
Revenue72.59M
Gross Profit72.59M
Operating Income-247.72M
Pretax Income-218.81M
Net Income-218.96M
EBITDA-212.18M
Earnings Per Share (EPS)-3.16
Cash Flow
In the last 12 months, operating cash flow was -228.90M and capital expenditures -106.68K, giving a free cash flow of -229.01M billion.
Operating Cash Flow-228.90M
Free Cash Flow-229.01M
Free Cash Flow per Share-4.55
Dividends & Yields
Bicycle Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.78
52-Week Price Change-48.88%
50-Day Moving Average4.82
200-Day Moving Average6.42
Relative Strength Index (RSI)34.33
Average Volume (3m)388.48K
Important Dates
Bicycle Therapeutics upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).
Last Earnings DateApr 30, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Bicycle Therapeutics as a current ratio of 11.02, with Debt / Equity ratio of 2.50%
Current Ratio11.02
Quick Ratio11.02
Debt to Market Cap<0.01
Net Debt to EBITDA2.88
Interest Coverage Ratio-1.20K
Taxes
In the past 12 months, Bicycle Therapeutics has paid 152.00K in taxes.
Income Tax152.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Bicycle Therapeutics EV to EBITDA ratio is 0.57, with an EV/FCF ratio of 0.48.
EV to Sales-1.65
EV to EBITDA0.57
EV to Free Cash Flow0.48
EV to Operating Cash Flow0.48
Balance Sheet
Bicycle Therapeutics has $559.47M in cash and marketable securities with $13.87M in debt, giving a net cash position of $545.60M billion.
Cash & Marketable Securities$559.47M
Total Debt$13.87M
Net Cash$545.60M
Net Cash Per Share$10.83
Tangible Book Value Per Share$8.80
Margins
Gross margin is -11.86%, with operating margin of -341.28%, and net profit margin of -301.66%.
Gross Margin-11.86%
Operating Margin-341.28%
Pretax Margin-301.45%
Net Profit Margin-301.66%
EBITDA Margin-292.32%
EBIT Margin-301.16%
Analyst Forecast
The average price target for Bicycle Therapeutics is $12.49, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$12.49
Price Target Upside134.39% Upside
Analyst ConsensusModerate Buy
Analyst Count8
Revenue Growth Forecast146.03%
EPS Growth Forecast-0.87%